Age-related Macular Degeneration Market Size, Share, Growth, and Industry Analysis, By Type (Wet AMD,Dry AMD), By Application (Drugstore,Hospital,Others), Regional Insights and Forecast to 2035

Age-related Macular Degeneration Market Overview

The global Age-related Macular Degeneration Market is forecast to expand from USD 13642.17 million in 2026 to USD 14647.6 million in 2027, and is expected to reach USD 25864.21 million by 2035, growing at a CAGR of 7.37% over the forecast period.

The global Age-related Macular Degeneration Market is witnessing an increasing prevalence with approximately 8,057,521 cases of low vision and blindness reported in 2021, compared to 3,640,180 in 1990. Age-standardized prevalence rates (ASPR) globally reached 94 per 100,000 in 2021. Disability-Adjusted Life Years (DALYs) associated with AMD rose from 302,902 in 1990 to 578,020 in 2021. Dry AMD represents 80% to 90% of cases worldwide, while wet AMD accounts for 10% to 15%. The burden of geographic atrophy affects approximately 1 million individuals in the U.S., emphasizing the need for advanced diagnostics, therapeutics, and early intervention strategies.

In the United States, 19.8 million Americans aged 40 and above have some form of AMD, with 1.49 million suffering from vision-threatening late-stage AMD. Early AMD affects around 18.34 million adults aged 50 and above. Among individuals aged 80 and older, 30% have early AMD and 10% have late AMD. Dry AMD accounts for 85% to 90% of all cases, with wet AMD representing 10% to 15%. Annually, 200,000 new cases of wet AMD are diagnosed in North America. Black Americans exhibit a lower prevalence of 7%, compared to 13.3% in other racial/ethnic groups aged 40 and above.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Driver: Dry AMD prevalence of 85%-90% globally; wet AMD 10%-15%.
• Major Market Restraint: Black American AMD prevalence 7%, other ethnicities 13.3%.
• Emerging Trends: Global low vision and blindness due to AMD rose to 8,057,521 cases.
• Regional Leadership: Asia reported 5,302,638 cases of low vision/blindness due to AMD.
• Competitive Landscape: Dry AMD 80%-90%, wet AMD 10%-15% of total cases globally.
• Market Segmentation: Late-stage AMD affects 1 in 100; early AMD 1 in 10 adults aged 50+.
• Recent Development: Annual wet AMD prevalence in U.S.: 1.2%-1.3% (2018-2021).

Age-related Macular Degeneration Market Trends

The Age-related Macular Degeneration Market is experiencing a significant rise in cases of low vision and blindness, from 3,640,180 in 1990 to 8,057,521 in 2021. DALYs increased from 302,902 to 578,020, while age-standardized DALY rates reached 6.78 per 100,000. In North America, 200,000 new wet AMD cases are diagnosed annually, with prevalence of 1.2%-1.3% among adults aged 50 and above. Early AMD affects 18.34 million U.S. adults aged 50+, while late AMD affects 1.49 million.

Dry AMD dominates 85%-90% of cases, whereas wet AMD accounts for 10%-15%. In Asia-Pacific, 5,302,638 cases of low vision and blindness were reported in 2021. Trends indicate that aging populations, stable wet AMD incidence, and rising global awareness of AMD diagnostics and therapeutics are driving market expansion. Increasing investments in imaging tools, nutritional supplements, and anti-VEGF therapies are shaping the Age-related Macular Degeneration Market Forecast, offering new opportunities in both hospital and retail applications.

Age-related Macular Degeneration Market Dynamics

DRIVER

"Rising prevalence with aging population"

A key driver of the Age-related Macular Degeneration Market is the aging population. In the U.S., individuals aged 85+ have a prevalence of 46.6% for any AMD, compared to 2% in the 40-44 age group. Globally, cases increased from 3,640,180 in 1990 to 8,057,521 in 2021. The growing proportion of older adults in high-income nations is fueling demand for diagnostics, therapeutics, and monitoring devices. Early AMD affects 18.34 million U.S. adults aged 50+, and late AMD affects 1.49 million, emphasizing a large target population for pharmaceutical and medical device companies.

RESTRAINT

"Wet AMD incidence plateau & lower prevalence in certain demographics"

Wet AMD incidence in the U.S. has remained stable at 1.2%-1.3% among adults aged 50+ from 2018-2021. Certain demographics, such as Black Americans, have a lower prevalence of 7%, compared to 13.3% for other ethnicities. Geographic atrophy affects 1 million people in the U.S., yet diagnostic and therapeutic advancements remain limited. The majority of AMD is dry type, which progresses slowly, reducing urgency for aggressive intervention. This demographic variation and disease type distribution restrain the market by limiting immediate treatment demand in certain populations.

OPPORTUNITY

"Emerging therapies and unmet need in late/dry AMD populations"

With 18.34 million adults in the U.S. affected by early AMD and 1.49 million with late-stage AMD, there is significant opportunity for therapies preventing progression. Globally, AMD-related low vision and blindness rose to 8,057,521 in 2021. Regions with lower socio-demographic index show higher DALYs, indicating unmet needs for diagnostics and treatments. Anti-VEGF therapies, complement inhibitors, and nutritional supplements present significant growth opportunities. Annual wet AMD cases of 200,000 in North America indicate a steady patient pool for ongoing treatment and monitoring, driving investment in therapeutics and clinical development pipelines.

CHALLENGE

"Lack of effective therapies for dry AMD progression and geographic atrophy"

Dry AMD comprises 80%-90% of cases globally, but treatment options for progression to geographic atrophy are limited. Approximately 1 million people in the U.S. have geographic atrophy, highlighting the challenge in managing late-stage dry AMD. Monitoring requires advanced imaging and follow-ups, which are resource-intensive. Prevalence varies across U.S. states from 6.2% to 18.3%, creating disparities in diagnosis and access to care. Low prevalence in certain demographics may lead to underdiagnosis and reduced commercial interest, further challenging market expansion.

Age-related Macular Degeneration Market Segmentation

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Dry AMD: Accounts for 80%-90% of global AMD cases. Early AMD affects 18.34 million adults aged 50+ in the U.S. Geographic atrophy impacts 1 million individuals. Prevalence rises from 2% (age 40-44) to 30% (age 80+). Dry AMD is largely managed with lifestyle interventions, nutritional supplements, and monitoring tools.

The Wet AMD segment is expected to maintain a substantial market share, driven by the increasing prevalence of neovascular AMD and advancements in anti-VEGF therapies.

Top 5 Major Dominant Countries in the Wet AMD Segment

• United States: The U.S. holds a significant share in the Wet AMD market, attributed to a high aging population and advanced healthcare infrastructure.
• Germany: Germany's robust healthcare system and aging demographic contribute to its leading position in the Wet AMD market.
• Japan: Japan's rapidly aging population and healthcare advancements position it as a key player in the Wet AMD market.
• France: France's healthcare policies and aging population support its significant role in the Wet AMD market.
• United Kingdom: The UK's healthcare system and aging demographic contribute to its notable presence in the Wet AMD market.

Wet AMD: Comprises 10%-15% of global AMD cases. Annually, 200,000 new wet AMD cases are diagnosed in North America. U.S. prevalence among adults aged 50+ remains 1.2%-1.3%. Treatment involves anti-VEGF therapy and hospital-based monitoring, representing a major portion of the hospital application segment.

The Dry AMD segment is anticipated to experience steady growth, driven by the increasing prevalence of geographic atrophy and advancements in nutritional therapies.

Top 5 Major Dominant Countries in the Dry AMD Segment

• United States: The U.S. leads in the Dry AMD market due to a significant aging population and ongoing research in nutritional therapies.
• Germany: Germany's advanced healthcare system and aging population contribute to its leadership in the Dry AMD market.
• Japan: Japan's aging demographic and healthcare advancements position it prominently in the Dry AMD market.
• France: France's healthcare policies and aging population support its significant role in the Dry AMD market.
• United Kingdom: The UK's healthcare system and aging demographic contribute to its notable presence in the Dry AMD market.

BY APPLICATION

Hospital/Ophthalmology Clinics: Majority of wet AMD cases are treated in hospitals due to anti-VEGF therapy requirements. Prevalence 1.2%-1.3% among adults aged 50+.

The Hospital segment is expected to dominate, driven by the increasing number of AMD-related hospital admissions and advancements in surgical interventions.

Top 5 Major Dominant Countries in the Hospital Application

• United States: The U.S. leads in the Hospital application segment due to advanced surgical interventions and high hospital admissions for AMD.
• Germany: Germany's advanced healthcare system and specialized eye care centers contribute to its leadership in the Hospital application.
• Japan: Japan's healthcare advancements and specialized medical facilities support its prominence in the Hospital application segment.
• France: France's healthcare infrastructure and specialized eye care services contribute to its role in the Hospital application.
• United Kingdom: The UK's healthcare system and specialized medical facilities support its position in the Hospital application segment.

Drugstore/Retail/Nutraceuticals: Nutritional supplements target early AMD, affecting 18.34 million adults aged 50+.

The Drugstore segment is projected to witness growth, driven by the increasing availability of over-the-counter supplements and medications for AMD management.

Top 5 Major Dominant Countries in the Drugstore Application

• United States: The U.S. leads in the Drugstore application segment due to widespread access to over-the-counter AMD treatments.
• Germany: Germany's well-established pharmaceutical retail sector contributes to its prominence in the Drugstore application.
• Japan: Japan's advanced healthcare infrastructure supports its significant role in the Drugstore application segment.
• France: France's healthcare policies and retail sector contribute to its leadership in the Drugstore application.
• United Kingdom: The UK's pharmaceutical retail sector and healthcare system support its position in the Drugstore application.

Others (Tele-ophthalmology/Diagnostics): Mobile imaging and home-based diagnostics serve areas with prevalence ranging from 6.2%-18.3%, particularly in low SDI regions, addressing gaps in access and early detection.

The 'Others' application segment encompasses emerging therapies and technologies, with potential growth driven by innovation in AMD treatment modalities.

Top 5 Major Dominant Countries in the 'Others' Application

• United States: The U.S. leads in the 'Others' application segment due to ongoing research and development in novel AMD therapies.
• Germany: Germany's strong emphasis on medical research and innovation contributes to its leadership in the 'Others' application.
• Japan: Japan's advancements in medical technology and research support its role in the 'Others' application segment.
• France: France's investment in medical research and development positions it prominently in the 'Others' application.
• United Kingdom: The UK's focus on medical innovation and research supports its position in the 'Others' application segment.

Age-related Macular Degeneration Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

NORTH AMERICA

19.8 million adults aged 40+ have AMD, 1.49 million with late-stage. Early AMD 18.34 million, late AMD 1.49 million, wet AMD prevalence 1.2%-1.3%, Black Americans 7%, other ethnicities 13.3%, ages 80+: early AMD 30%, late AMD 10%.

North America holds a significant share of the global AMD market, driven by a high prevalence of AMD and advanced healthcare infrastructure.

North America - Major Dominant Countries in the Age-related Macular Degeneration Market

• United States: The U.S. dominates the North American AMD market due to a high aging population and advanced healthcare facilities.
• Canada: Canada's healthcare system and aging demographic contribute to its significant role in the AMD market.

EUROPE

Aging population leads to significant AMD burden; prevalence rates in high-income nations show ASPR ~ 48.43 per 100,000. Advanced diagnostics improve wet AMD treatment access.

Europe exhibits steady growth in the AMD market, influenced by an aging population and advancements in treatment options.

Europe - Major Dominant Countries in the Age-related Macular Degeneration Market

• Germany: Germany leads in the European AMD market due to its advanced healthcare system and aging population.
• France: France's healthcare policies and aging demographic support its prominence in the AMD market.
• United Kingdom: The UK's healthcare system and aging population contribute to its significant role in the AMD market.
• Italy: Italy's aging population and healthcare advancements position it prominently in the AMD market.
• Spain: Spain's healthcare infrastructure and aging demographic support its position in the AMD market.

ASIA-PACIFIC

5,302,638 cases of low vision/blindness due to AMD in 2021. Rising elderly populations in China, India, and Japan drive demand for diagnostics and therapeutics.

Asia is experiencing rapid growth in the AMD market, driven by an aging population and increasing healthcare access.

Asia - Major Dominant Countries in the Age-related Macular Degeneration Market

• Japan: Japan leads in the Asian AMD market due to a rapidly aging population and advanced healthcare infrastructure.
• China: China's large aging demographic and expanding healthcare access contribute to its prominence in the AMD market.
• India: India's growing elderly population and improving healthcare facilities support its role in the AMD market.
• South Korea: South Korea's aging population and healthcare advancements position it as a key player in the AMD market.
• Australia: Australia's healthcare system and aging demographic contribute to its significant presence in the AMD market.

MIDDLE EAST & AFRICA

Prevalence is lower than high-income regions, but limited healthcare infrastructure results in higher DALYs. Early interventions are increasing, creating market potential.

The Middle East and Africa region is witnessing gradual growth in the AMD market, influenced by an aging population and improving healthcare infrastructure.

Middle East and Africa - Major Dominant Countries in the Age-related Macular Degeneration Market

• South Africa: South Africa leads in the African AMD market due to its developing healthcare infrastructure and aging population.
• Saudi Arabia: Saudi Arabia's healthcare advancements and aging demographic contribute to its role in the AMD market.
• United Arab Emirates: The UAE's healthcare system and aging population support its position in the AMD market.
• Egypt: Egypt's healthcare infrastructure and aging demographic contribute to its presence in the AMD market.
• Nigeria: Nigeria's developing healthcare system and aging population support its role in the AMD market.

List of Top Age-related Macular Degeneration Companies

• Hoffmann-La Roche
• Iconic Therapeutics
• Ohr Pharmaceutical
• Regeneron Pharmaceuticals
• Neurotech Pharmaceuticals
• Allergan
• Bausch+Lomb
• Novartis
• Gilead Sciences
• Bayer HealthCare
• Alcon
• Avalanche

Hoffmann-La Roche – Dominates global wet AMD treatment with anti-VEGF therapies, capturing the largest market share.

Regeneron Pharmaceuticals – Second-largest, with extensive portfolio in anti-VEGF treatments for wet AMD.

Investment Analysis and Opportunities

Investments in the Age-related Macular Degeneration Market focus on drug development, imaging tools, and diagnostics. With 8,057,521 global cases of low vision/blindness in 2021 and 18.34 million U.S. adults affected by early AMD, there is substantial opportunity for therapies, diagnostics, and preventive care. Anti-VEGF injections dominate wet AMD treatment, while novel therapeutics are emerging for geographic atrophy and dry AMD progression. Tele-ophthalmology, mobile imaging devices, and at-home monitoring systems are gaining traction, particularly in regions with prevalence rates ranging from 6.2%-18.3%.

Nutraceuticals targeting early AMD offer a supplementary market, addressing 18.34 million potential patients in the U.S. Annual 200,000 new wet AMD cases in North America ensure a consistent treatment population. Market expansion is supported by rising elderly populations in Asia-Pacific and Europe, where prevalence continues to increase. Overall, the Age-related Macular Degeneration Market Forecast highlights growing investment opportunities in therapeutics, diagnostics, and preventive interventions.

New Product Development

Recent product development in the Age-related Macular Degeneration Market focuses on anti-VEGF therapies, complement inhibitors, and advanced imaging devices. Anti-VEGF injections treat wet AMD, addressing the 10%-15% of patients affected. For dry AMD, research targets geographic atrophy, affecting 1 million U.S. adults. Nutraceutical supplements are being formulated for early AMD prevention, impacting 18.34 million adults aged 50+ in the U.S.

Telemedicine and mobile OCT imaging devices are emerging in regions with 6.2%-18.3% prevalence, enhancing early diagnosis. Innovations in home-based monitoring and digital platforms enable timely intervention, particularly in Asia-Pacific where 5,302,638 low vision/blindness cases exist. Hospital-based solutions continue to advance with precise imaging and drug delivery systems for wet AMD (1.2%-1.3% prevalence). These developments expand the Age-related Macular Degeneration Market Analysis opportunities across hospital, retail, and remote healthcare applications.

Five Recent Developments

• Launch of a next-generation anti-VEGF therapy for wet AMD in North America with annual treatment population 200,000.
• Introduction of a mobile OCT device for early AMD detection targeting 18.34 million adults aged 50+ in U.S.
• Expansion of tele-ophthalmology services in Asia-Pacific serving 5,302,638 low vision/blindness cases.
• Clinical trials of complement inhibitors for geographic atrophy affecting 1 million U.S. patients.
• Development of nutraceutical formulations targeting early AMD among 18.34 million adults in North America.

Report Coverage of Age-related Macular Degeneration Market

The Age-related Macular Degeneration Market Report provides a detailed scope covering prevalence, patient demographics, disease type, and therapeutic segmentation. It includes global, regional, and country-level prevalence, highlighting the 19.8 million U.S. adults aged 40+ affected and 5,302,638 cases in Asia-Pacific. The report examines dry AMD (80%-90%) and wet AMD (10%-15%) by type, alongside hospital, retail, and remote applications. Key market drivers such as aging population and rising case numbers are analyzed alongside restraints like demographic disparities and plateaued wet AMD incidence (1.2%-1.3%). Investment opportunities are outlined in therapeutics, imaging, tele-ophthalmology, and nutraceuticals. New product innovations, including anti-VEGF therapies, complement inhibitors, and home monitoring devices, are detailed, with a focus on 18.34 million early AMD patients in the U.S. and 1.49 million late AMD cases. Regional performance and market segmentation are included, providing actionable insights for stakeholders seeking market entry, expansion, or partnership. The report also identifies competitive landscape and leading companies, including F. Hoffmann-La Roche and Regeneron Pharmaceuticals, dominating wet AMD treatment globally. The coverage ensures a comprehensive understanding of market size, share, trends, and opportunities across North America, Europe, Asia-Pacific, and Middle East & Africa, providing B2B stakeholders with insights to strategize effectively in the Age-related Macular Degeneration Market Analysis and Market Insights landscape.

Age-related Macular Degeneration Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 13642.17 Million in 2026
Market Size Value By	USD 25864.21 Million by 2035
Growth Rate	CAGR of 7.37% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Wet AMD Dry AMD By Application : Drugstore Hospital Others
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample